Study wrapper · #609
The cardiovascular action of hexarelin.
Editor's note
This concise review focuses directly on hexarelin's cardiovascular actions. It explains that hexarelin binds the GHS receptor in the brain like its natural analog ghrelin, but that GHSR and the non-GHSR receptor CD36 are also present in the heart and vessels, suggesting direct cardiovascular effects beyond growth-hormone release. The authors note hexarelin is chemically more stable and more potent than ghrelin, positioning it as a candidate for certain cardiovascular conditions. As an on-topic review it is a useful anchor for hexarelin's editorial profile, but it is not primary evidence and summarizes a literature that is almost entirely preclinical. Human data would be needed before any clinical conclusions about hexarelin's cardiovascular use.
Plain-language abstract
This is a short review article about how hexarelin, a synthetic peptide, affects the heart and blood vessels. It explains that hexarelin acts on the same brain receptor as the natural hormone ghrelin, but that this receptor, plus another one called CD36, is also found in the heart and vessels, which suggests hexarelin can act directly on the cardiovascular system, not just by releasing growth hormone. The authors point out hexarelin is more chemically stable and more potent than ghrelin, making it a possible candidate for some heart conditions. This is a summary of existing research, most of it in animals and cells, so human studies would be needed before any clinical conclusions could be drawn.